CN100344648C - 环孢菌素类似物混合物及其在制备免疫调节剂中的用途 - Google Patents

环孢菌素类似物混合物及其在制备免疫调节剂中的用途 Download PDF

Info

Publication number
CN100344648C
CN100344648C CNB02820798XA CN02820798A CN100344648C CN 100344648 C CN100344648 C CN 100344648C CN B02820798X A CNB02820798X A CN B02820798XA CN 02820798 A CN02820798 A CN 02820798A CN 100344648 C CN100344648 C CN 100344648C
Authority
CN
China
Prior art keywords
isomer
mixture
use according
cyclosporin
cyclosporine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB02820798XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1571794A (zh
Inventor
S·奈克
R·W·亚茨科夫
R·T·福斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
697937 Alberta Co ltd
Aesop Pharmaceutical Ltd By Share Ltd
Paladin Laboratories Ltd
Aurinia Pharmaceuticals Inc
Original Assignee
Isoteknica Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isoteknica Co ltd filed Critical Isoteknica Co ltd
Publication of CN1571794A publication Critical patent/CN1571794A/zh
Application granted granted Critical
Publication of CN100344648C publication Critical patent/CN100344648C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
CNB02820798XA 2001-10-19 2002-10-17 环孢菌素类似物混合物及其在制备免疫调节剂中的用途 Expired - Lifetime CN100344648C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34620101P 2001-10-19 2001-10-19
US60/346,201 2001-10-19

Publications (2)

Publication Number Publication Date
CN1571794A CN1571794A (zh) 2005-01-26
CN100344648C true CN100344648C (zh) 2007-10-24

Family

ID=23358378

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB02820798XA Expired - Lifetime CN100344648C (zh) 2001-10-19 2002-10-17 环孢菌素类似物混合物及其在制备免疫调节剂中的用途

Country Status (38)

Country Link
US (2) US20110092669A1 (cg-RX-API-DMAC7.html)
EP (2) EP1436322B1 (cg-RX-API-DMAC7.html)
JP (4) JP2005511538A (cg-RX-API-DMAC7.html)
KR (1) KR100992850B1 (cg-RX-API-DMAC7.html)
CN (1) CN100344648C (cg-RX-API-DMAC7.html)
AR (1) AR036853A1 (cg-RX-API-DMAC7.html)
AT (1) ATE401339T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002331510B2 (cg-RX-API-DMAC7.html)
BE (1) BE2022C547I2 (cg-RX-API-DMAC7.html)
BR (1) BR0213659A (cg-RX-API-DMAC7.html)
CA (2) CA2727642C (cg-RX-API-DMAC7.html)
CO (1) CO5570682A2 (cg-RX-API-DMAC7.html)
CY (2) CY1108410T1 (cg-RX-API-DMAC7.html)
DE (1) DE60227686D1 (cg-RX-API-DMAC7.html)
DK (1) DK1436322T3 (cg-RX-API-DMAC7.html)
EC (3) ECSP045059A (cg-RX-API-DMAC7.html)
ES (1) ES2310604T3 (cg-RX-API-DMAC7.html)
FI (1) FIC20220041I1 (cg-RX-API-DMAC7.html)
FR (1) FR22C1051I2 (cg-RX-API-DMAC7.html)
HR (1) HRP20040353B1 (cg-RX-API-DMAC7.html)
IL (2) IL160762A0 (cg-RX-API-DMAC7.html)
LT (1) LTC1436322I2 (cg-RX-API-DMAC7.html)
MA (1) MA26337A1 (cg-RX-API-DMAC7.html)
ME (1) ME00487B (cg-RX-API-DMAC7.html)
MX (1) MXPA04003624A (cg-RX-API-DMAC7.html)
MY (1) MY187182A (cg-RX-API-DMAC7.html)
NL (1) NL301200I2 (cg-RX-API-DMAC7.html)
NO (2) NO331745B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ531945A (cg-RX-API-DMAC7.html)
PL (1) PL210697B1 (cg-RX-API-DMAC7.html)
PT (1) PT1436322E (cg-RX-API-DMAC7.html)
PY (2) PY0225477A (cg-RX-API-DMAC7.html)
RU (1) RU2337106C2 (cg-RX-API-DMAC7.html)
SI (1) SI1436322T1 (cg-RX-API-DMAC7.html)
TN (1) TNSN04069A1 (cg-RX-API-DMAC7.html)
UY (1) UY27502A1 (cg-RX-API-DMAC7.html)
WO (1) WO2003033527A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200402270B (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1436322T3 (da) * 2001-10-19 2008-11-03 Isotechnika Inc Blandinger af cyclosporinanaloger og deres anvendelse som immunmodulerende midler
HRP20070058B1 (hr) 2001-10-19 2014-05-23 Isotechnika Inc. Sinteza ciklosporinskih analoga
CA2518265A1 (en) 2003-03-17 2004-09-30 Albany Molecular Research, Inc. Novel cyclosporins
TW200505946A (en) * 2003-04-08 2005-02-16 Hoffmann La Roche Process for preparation of cyclosporin a analog
US7378391B2 (en) 2004-09-29 2008-05-27 Amr Technology, Inc. Cyclosporin alkyne analogues and their pharmaceutical uses
JP2008514702A (ja) 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド 新規シクロスポリン類似体およびそれらの薬学的使用
WO2006041631A2 (en) 2004-10-06 2006-04-20 Amr Technology, Inc. Novel cyclosporin alkynes and their utility as pharmaceutical agents
TW200635954A (en) * 2004-12-17 2006-10-16 Isotechnika Inc Metabolites of cyclosporin analogs
KR101273681B1 (ko) * 2005-10-26 2013-06-25 아스텔라스세이야쿠 가부시키가이샤 신규 시클릭 펩티드 화합물
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
EP2150269B1 (en) * 2007-05-02 2012-11-21 Astellas Pharma Inc. New cyclic peptide compounds
JP5668476B2 (ja) 2007-10-08 2015-02-12 オーリニア・ファーマシューティカルズ・インコーポレイテッドAurinia Pharmaceuticals Inc. カルシニューリン阻害剤またはmTOR阻害剤を含む眼科用組成物
RU2361604C1 (ru) * 2007-10-29 2009-07-20 Федеральное агентство по высокотехнологичной медицинской помощи Федеральное государственное учреждение "Уральский научно-исследовательский институт дерматовенерологии и иммунопатологии" (ФГУ УрНИИДВиИ Росмедтехнологий) Способ лечения атопического дерматита
EP2440185B1 (en) 2009-06-09 2015-04-08 Aurinia Pharmaceuticals Inc. Topical drug delivery systems for ophthalmic use
GB0912584D0 (en) * 2009-07-20 2009-08-26 Ucl Business Plc Cyclosporin conjugates
AU2011342284C1 (en) 2010-12-15 2017-07-13 Contravir Pharmaceuticals, Inc. Cyclosporine analogue molecules modified at amino acid 1 and 3
GB201222455D0 (en) * 2012-12-13 2013-01-30 Perioc Ltd Novel pharmaceutical formulations and their use in the treatment of periodontaldisease
EP3549051A4 (en) * 2016-11-30 2020-04-29 Schrodinger, Inc. GRAPHIC USER INTERFACE FOR CALCULATING CHEMICAL TRANSITIONAL STATES
CA3045944A1 (en) 2016-12-07 2018-06-14 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
WO2018106928A1 (en) 2016-12-08 2018-06-14 Contravir Pharmaceuticals, Inc. Treatment and prevention of hbv diseases by cyclosporine analogue molecules modified at amino acides 1 and 3
US11523772B2 (en) 2016-12-14 2022-12-13 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immunosuppressant
US10286036B2 (en) * 2017-05-12 2019-05-14 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
CA3172535A1 (en) * 2020-03-26 2021-09-30 Ching-Pong Mak Cyclophilin inhibitors and uses thereof
EP4201952A1 (en) 2021-12-21 2023-06-28 Curia Spain, S.A.U. Process for the controlled synthesis of voclosporin
WO2024052941A1 (en) * 2022-09-09 2024-03-14 Dr. Reddy's Laboratories Limited Improved process for the preparation of voclosporin
IT202300001056A1 (it) * 2023-01-25 2024-07-25 Procos Spa Nuovo processo per la preparazione di voclosporina amorfa
IT202300001116A1 (it) * 2023-01-25 2024-07-25 Indena Spa Processo per la preparazione di un intermedio utile per la sintesi di voclosporina
WO2025119925A1 (en) 2023-12-05 2025-06-12 Medichem, S.A. Process for preparing voclosporin
IT202300028041A1 (it) * 2023-12-27 2025-06-27 Indena Spa Processo per la preparazione di voclosporina

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0026122A1 (en) * 1979-09-12 1981-04-01 Fram Industrial Filter Corporation Apparatus for separating solids and liquid components
WO1999018120A1 (en) * 1997-10-08 1999-04-15 Isotechnika Inc. Deuterated cyclosporine analogs and their use as immunomodulating agents

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH670644A5 (cg-RX-API-DMAC7.html) * 1986-12-18 1989-06-30 Lonza Ag
US5162540A (en) * 1986-12-18 1992-11-10 Lonza Ltd. Process for the production of (+) biotin
ATE95193T1 (de) * 1987-06-17 1993-10-15 Sandoz Ag Cyclosporine und deren benutzung als arzneimittel.
US5972630A (en) * 1991-08-19 1999-10-26 Dade Behring Marburg Gmbh Homogeneous immunoassays using enzyme inhibitors
GB9204466D0 (en) * 1992-03-02 1992-04-15 Sandoz Ltd Improvements in or relating to organic compounds
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
US5750510A (en) * 1997-04-04 1998-05-12 Abbott Laboratories 3-descladinose-2,3-anhydroerythromycin derivatives
DK0869810T3 (da) * 1996-06-19 2005-02-07 Novartis Ag Cyclosporinholdige blöde kapselpræparater
US5939406A (en) * 1997-07-21 1999-08-17 Wisconsin Alumni Research Foundation 18-substituted-19-nor-vitamin D compounds
HRP20070058B1 (hr) * 2001-10-19 2014-05-23 Isotechnika Inc. Sinteza ciklosporinskih analoga
DK1436322T3 (da) * 2001-10-19 2008-11-03 Isotechnika Inc Blandinger af cyclosporinanaloger og deres anvendelse som immunmodulerende midler

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0026122A1 (en) * 1979-09-12 1981-04-01 Fram Industrial Filter Corporation Apparatus for separating solids and liquid components
WO1999018120A1 (en) * 1997-10-08 1999-04-15 Isotechnika Inc. Deuterated cyclosporine analogs and their use as immunomodulating agents

Also Published As

Publication number Publication date
PY0225478A (es) 2004-05-03
RU2004110941A (ru) 2005-08-10
ZA200402270B (en) 2005-05-25
FR22C1051I1 (fr) 2022-12-16
ES2310604T3 (es) 2009-01-16
KR20050037421A (ko) 2005-04-21
IL160762A0 (en) 2004-08-31
ECSP045059A (es) 2004-07-23
PL370501A1 (en) 2005-05-30
JP2009197036A (ja) 2009-09-03
ATE401339T1 (de) 2008-08-15
ECSP045060A (es) 2004-07-23
JP5272140B2 (ja) 2013-08-28
US20110092669A1 (en) 2011-04-21
NL301200I2 (nl) 2024-07-25
ME00487B (me) 2011-10-10
CA2727642A1 (en) 2003-04-24
HRP20040353B1 (hr) 2012-10-31
FR22C1051I2 (fr) 2023-11-17
AU2002331510B2 (en) 2008-05-01
EP1436322A2 (en) 2004-07-14
ECSP045061A (es) 2004-08-27
AR036853A1 (es) 2004-10-06
US20140288266A1 (en) 2014-09-25
DK1436322T3 (da) 2008-11-03
NZ531945A (en) 2006-01-27
CY2022030I1 (el) 2023-01-27
PT1436322E (pt) 2008-10-23
IL160762A (en) 2010-11-30
KR100992850B1 (ko) 2010-11-09
LTC1436322I2 (cg-RX-API-DMAC7.html) 2023-06-26
EP1816138A1 (en) 2007-08-08
DE60227686D1 (de) 2008-08-28
PY0225477A (es) 2004-05-03
RU2337106C2 (ru) 2008-10-27
CY2022030I2 (el) 2023-06-09
CA2460685C (en) 2014-05-27
HK1062567A1 (en) 2004-11-12
WO2003033527A3 (en) 2003-10-16
CA2727642C (en) 2014-02-04
BR0213659A (pt) 2004-10-26
HRP20040353A2 (en) 2005-04-30
BE2022C547I2 (cg-RX-API-DMAC7.html) 2022-10-19
CN1571794A (zh) 2005-01-26
CY1108410T1 (el) 2012-05-23
LTPA2022521I1 (cg-RX-API-DMAC7.html) 2022-11-10
CO5570682A2 (es) 2005-10-31
NO20042029L (no) 2004-05-14
PL210697B1 (pl) 2012-02-29
CA2460685A1 (en) 2003-04-24
JP2005511538A (ja) 2005-04-28
TNSN04069A1 (en) 2006-06-01
JP2013136597A (ja) 2013-07-11
MY187182A (en) 2021-09-08
EP1436322B1 (en) 2008-07-16
NO2022042I1 (no) 2022-10-14
SI1436322T1 (sl) 2008-12-31
WO2003033527A2 (en) 2003-04-24
MA26337A1 (fr) 2004-10-01
JP2011006417A (ja) 2011-01-13
UY27502A1 (es) 2003-04-30
FIC20220041I1 (fi) 2022-10-14
NO331745B1 (no) 2012-03-19
MXPA04003624A (es) 2004-12-06

Similar Documents

Publication Publication Date Title
CN1571795A (zh) 环孢菌素类似物的合成
CN1571794A (zh) 环孢菌素类似物混合物及其作为免疫调节剂的用途
CN1274294C (zh) 环孢菌素类似物微乳液预浓缩物
AU2002331510A1 (en) Cyclosporine analogue mixtures and their use as immunomodulating agents
HK1062567B (en) Cyclosporine analogue mixtures and their use as immunomodulating agents

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: PALADIN LABS INC.

Free format text: FORMER OWNER: 697937 ALBERTA LTD.

Effective date: 20150605

Owner name: ISOTECHNIKA PHARMA INC.

Free format text: FORMER OWNER: PALADIN LABS INC.

Effective date: 20150605

C41 Transfer of patent application or patent right or utility model
C56 Change in the name or address of the patentee

Owner name: 697937 ALBERTA LTD.

Free format text: FORMER NAME: ISOTECHNIKA INC.

Owner name: ORINIA PHARMACEUTICAL CO., LTD.

Free format text: FORMER NAME: ISOTECHNIKA PHARMA INC.

CP01 Change in the name or title of a patent holder

Address after: Alberta Canada

Patentee after: 697937 Alberta Co.,Ltd.

Address before: Alberta Canada

Patentee before: Isoteknica Co.,Ltd.

CP03 Change of name, title or address

Address after: British Columbia Canada

Patentee after: Aurinia Pharmaceuticals Inc.

Address before: Alberta Canada

Patentee before: Aesop pharmaceutical Limited by Share Ltd.

TR01 Transfer of patent right

Effective date of registration: 20150605

Address after: Alberta Canada

Patentee after: Aesop pharmaceutical Limited by Share Ltd.

Address before: Quebec

Patentee before: Paladin laboratories Ltd.

Effective date of registration: 20150605

Address after: Quebec

Patentee after: Paladin laboratories Ltd.

Address before: Alberta Canada

Patentee before: 697937 Alberta Co.,Ltd.

CX01 Expiry of patent term

Granted publication date: 20071024

CX01 Expiry of patent term